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Abstract 
Obstructive sleep apnoea (OSA) is very common in patients with Type 2 diabetes (T2D) which is 
unsurprising given that obesity is a major risk factor for both conditions. OSA has been associated 
with impaired quality of life, many cardiovascular disease risk factors and cardiovascular disease in 
general.  
Continuous positive airway pressure (CPAP) treatment has beneficial impacts on CVD risk factors and 
CVD. However, the true impact of OSA in patients with T2D remains unclear. The International 
Diabetes Federation (IDF) recommended routine screening for OSA in patients with T2D but two-
thirds of diabetes healthcare professionals were unaware of these recommendations.  The aim of 
this review is to attempt to answer the following questions: is OSA diagnosis and treatment 
important in patients with T2D and why? Therefore what is the relevance of OSA to the practicing 
Diabetologist? 
Abbreviations 
AHI: Apnoea hypopnea index 
BMI: Body mass index 
BP: Blood pressure 
CAD: Coronary artery disease 
CI: Confidence interval 
CPAP: Continuous positive airway pressure 
CVD: Cardiovascular disease 
DN: Diabetic nephropathy 
DR: Diabetic retinopathy 
ED: Erectile dysfunction 
EDS: Excessive daytime sleepiness 
ESS: Epworth sleepiness score 
HIF-1: Hypoxia-inducible factor-1 
IR: insulin resistance 
NAFLD: Non-alcoholic fatty liver disease 
NASH: Non-alcoholic steatohepatitis 
ODI: Oxygen desaturation index 
OGTT: Oral glucose tolerance test 
OR: Odds ratio 
OSA: obstructive sleep apnoea 
QOL: Quality of life 
SREBP-1: Sterol regulatory element–binding protein  
T2D: Type 2 diabetes 
Introduction 
OSA affects 17–26% of men and 9–28% of women in population-based epidemiologic studies.1 It is 
characterised by upper airway instability during sleep that causes recurrent complete or partial 
upper airway obstruction resulting in recurrent episodes of either complete (apnoea) or partial 
(hypopnea) cessation of airflow.2 Apnoeas and hypopneas are associated with recurrent oxygen 
desaturations, cyclical changes in intra-thoracic pressure (as the patient attempts to breath against a 
blocked airway), BP, heart rate and sympathetic activity and recurrent micro-arousals (due to 
attempts to open the obstructed airways) that cause sleep fragmentation and disturbs the sleep 
architecture.2 An AHI (Apnoea hypopnea index) represents the average number apnoea and 
hypopnea episodes/hour during sleep: ≥ 5 events/hour is consistent with the diagnosis of OSA,2;3 
while AHI cut offs of 15 and 30 indicate moderate and severe OSA.4 Other measures of OSA include 
the ODI (Oxygen Desaturation Index), the average number of oxygen desaturations/hour of sleep 
(3% or 4% depending on the definition used), the lowest nocturnal oxygen saturations and the time 
spent with oxygen saturation <90%. Weight loss and CPAP are the mainstay treatments of OSA. 
Mandibular advancement devices can also be used in patients with mild OSA or those intolerant to 
CPAP. 
Snoring and witnessed apnoeas are common symptoms of OSA, with snoring reported in 95% of 
patients.2 EDS, though associated with OSA, seems to have stronger associations with depression 
and the metabolic syndrome.2;5 Other symptoms such as choking, insomnia, nocturia, sweating, 
fatigue, morning headache, erectile dysfunction and autonomic symptoms have been reported.2;6. 
Many of these are also common in T2D and contribute to the burden of disease. OSA should be 
considered as a cause of such symptoms in patients with T2D after ruling out hypo or hyper 
glycaemia as CPAP treatment can improve these symptoms. 
Obesity is a common risk factor for OSA and T2D,7 and the prevalence of OSA is high in people with 
type 2 diabetes (8.5–85%, with 23.8–70% for moderate-to-severe OSA).8-14 This wide range reflects 
differences in the population examined (primary vs. secondary care, ethnicities, gender, obesity 
etc.), the methods used to diagnose OSA (patients' records, questionnaires, oximetry, portable 
multi-channel cardiovascular monitoring devices or “gold standard” polysomnography) and the OSA 
definitions used (AHI vs. ODI, different cut-offs) 4;14. It is not clear, however, whether the prevalence 
of OSA in patients with T2D is higher than expected for patients with similar adiposity but without 
T2D. A recent cross-sectional analysis of the European Sleep Apnea Cohort (ESADA; n=6,616) 
suggested that T2D prevalence, adjusted for obesity and other potential confounders, increased with 
worsening OSA: odds ratios (OR, 95%CI) were 1.33 (1.04-1.72) for mild OSA, 1.73 (1.33-2.25) for 
moderate OSA and 1.87 (1.45-2.42) for severe OSA (p<0.001).15 
In 2008, the International Diabetes federation (IDF) recommended routine screening for OSA in 
patients with T2D,16 but two-thirds of diabetes healthcare professionals were unaware of these 
recommendations or that the local diabetes guidelines did not incorporate assessment for OSA in 
those at risk.17 Nonetheless, the impact of OSA in patients with T2D, how to screen and the benefits 
of screening are still unclear. 
The impact of OSA on glucose metabolism, and pre-diabetes and the consequences of having OSA in 
general population studies have been reviewed elsewhere.4;18 The aim of this article is to attempt to 
answer the following questions: is OSA diagnosis and treatment is important in patients with T2D 
and why? What is the relevance of OSA to the practicing Diabetologist?  
OSA is a risk factor for T2D 
Many cross-sectional studies in the general population19-28 and patients with T2D29;30 showed an 
association between OSA and IR, but others did not.31-33. These conflicting results are partly due to 
variation in the population examined, sample size (studies that did not show an association were 
smaller)14 or because of variation in excessive daytime sleepiness (EDS), which is associated with 
IR.34;35 Obesity did not explain fully the association between OSA and IR; many studies adjusted for 
obesity measures, OSA was associated with IR in lean men, and OSA can be caused by conditions 
other than obesity (e.g. acromegaly).36-38  
One longitudinal study showed that OSA, AHI, ODI and minimal nocturnal oxygen saturations were 
independent predictors of worsening IR (>75th percentile of change in HOMA-IR) over an 11-year 
follow-up after adjustment for age, baseline BMI, hypertension, BMI change over follow-up and 
CPAP39.  
The impact of OSA on β-cell dysfunction in humans is limited. A cross-sectional study showed that 
OSA was associated with impaired β-cell function in patients with30 or without diabetes.40  
In addition, OSA is associated with NAFLD and NASH 27;41. 
OSA predicts the development of incident T2D independently of age, obesity or other 
confounders39;42-46 and 8 hours/night of CPAP improved post-load glycaemia (OGTT) insulin 
sensitivity, 24 h BP and norepinephrine levels in a randomized, placebo-controlled trial.47 However, 
this study was conducted in the laboratory environment to ensure the high compliance with CPAP 
and the effects of CPAP on the incidence of T2D in uncontrolled settings remains to be determined. 
OSA is associated with worse glycaemic control in patients with T2D 
Cross-sectional studies show that OSA is associated with poorer glycaemic control, despite 
adjustments for age, sex, race, BMI, number of medications, exercise, diabetes duration and total 
sleep time.15;48-50. Lower nocturnal oxygen saturations were associated with higher HbA1c values in 
one study.51 but elsewhere there was no association between OSA and HbA1c,52 likely because only 
22% of participants had full polysomnography and the duration of the sleep study was just 4 hours.53 
Prospective studies assessing the impact of OSA on glycaemic measures longitudinally in patients 
with T2D are lacking. 
OSA is associated with hypertension  
Extensive epidemiological studies and interventional trials in the general population, but only limited 
data in patients with T2D, have associated OSA with hypertension and non-dipping BP.4;18;54 The 
Wisconsin Sleep Cohort Study Longitudinal found adjusted ORs for incident hypertension between 
1.42 and 2.89 with increasing AHI (vs. AHI=0 at baseline, p=0002 for the trend).55 Long-term (7 years) 
mild and moderate OSA (vs. AHI <5) increased the risk of incident nocturnal non-dipping BP about 3-
fold and 4-fold, respectively in a subgroup of patients.56. A large, cross-sectional study showed that 
OSA was more prevalent in T2D patients with awake BP ≥135/85  mmHg or asleep BP ≥120/70 
 mmHg, compared with lower BP57, suggesting a link between OSA and hypertension in T2D. 
 
OSA is associated with hyperlipidaemia 
A mechanistic link between OSA and hyperlipidaemia is plausible as chronic intermittent hypoxia 
could lead to the generation of stearoyl-coenzyme A desaturase-1, oxidative stress, peroxidation of 
lipids and sympathetic activation.58 However, cross-sectional studies were not consistent mainly due 
to differences in the population examined, studies designs and the impact of CPAP.58;59 A meta-
analysis of 64 studies showed that OSA was associated with higher total cholesterol, higher LDL, 
higher triglycerides and lower HDL, while AHI correlated positively with triglycerides and negatively 
with HDL levels only59 The association between OSA/AHI and triglycerides is obesity independent.60 
Longitudinal studies are lacking. 
OSA is associated with CVD  
General population 
OSA has been associated with a larger atherosclerotic plaque volume, with AHI correlating positively 
with plaque volume.61;62 OSA increased the risk of acute myocardial infarction overnight, supporting 
a role for nocturnal OSA events in the development of CVD.63 Prospective observational studies (3–
10 years of follow-up) have shown that OSA predicts the development of incident CVD, with 
adjusted OR/HR for incident CVD of 1.97–4.9.64-69  
Age and gender may modulate the relationship between OSA and incident CVD, as suggested by 
observational cohort studies in which OSA predicted incident CAD only in men aged <70 years and 
predicted heart failure in only in men,69 or was associated with stroke incidence only in men.70 
However, a study that included women only showed  that untreated OSA predicted a combined 
outcome of incident stroke and CAD, driven only by increased risk of stroke.71  
In patients with T2D 
AHI was associated with history of stroke (adjusted OR 2.57, 95 % CI 1.03–6.42), but not with CAD In 
a cross-sectional analysis from the Look AHEAD study.72 A prospective observational study of 132 
consecutive asymptomatic patients with T2D and OSA was associated with incident CAD (adjusted 
HR 2.2, 95 % CI 1.2–3.9, p=0.01) and heart failure (adjusted HR 3.5, 95 % CI 1.4–9.0; p<0.01) over a 
median follow-up of 4.9 years.73  
OSA is associated with diabetes-related microvascular complications  
The link between OSA and microvascular complications is plausible.  Intermittent hypoxaemia can 
result in increased oxidative and nitrosative stress, poly-(ADP-ribose) polymerase (PARP) activation, 
increased advanced glycation end-products, protein kinase C activation and inflammation in patients 
with and without diabetes – all of which can result in endothelial dysfunction and microvascular 
disease.4;11;54 
OSA and diabetic retinopathy (DR) 
In Japanese patients undergoing vitreous surgery for advanced DR, lower oxygen saturations were 
associated with proliferative DR after adjustment for age, HbA1c and hypertension.74 Cross-sectional 
data from the UK suggest that OSA may be independently associated with DR and maculopathy.75,76 
Longitudinally, patients with OSA were more likely to develop pre-proliferative/proliferative DR than 
those with T2D.76  
OSA and diabetic nephropathy  
In a cross-sectional study of Japanese patients with T2D, ODI ≥5 was independently associated with 
microalbuminuria in women but not in men after adjustment for confounders.77. In another cross-
sectional study, OSA was associated with DN in patients with T2D (adjusted OR 2.64, 95%CI 1.13-
6.16, p=0.02).78 Longitudinally, the eGFR decline was greater in patients with vs. without OSA 
(p=0.003). OSA was an independent predictor of study-end eGFR and eGFR decline.  
OSA and diabetic neuropathy 
A cross-sectional study found  that patients with vs. without OSA were more likely to have diabetic 
neuropathy (OR 2.82, 95%CI, 1.44–5.52) and foot insensitivity (OR 3.97; 95%CI, 1.80–8.74).11  
OSA is associated with impaired quality of life (QoL) 
Several cross-sectional studies showed that OSA, its severity, and nocturnal hypoxaemia were 
associated with worse QoL independent of EDS.79;80 This association might be modulated by age.79  
OSA is associated with increased risk of road traffic accidents (RTA) 
There is extensive evidence using driving stimulators and insurance databases showing an 
association between OSA and RTA and that CPAP treatment lowers the risk of RTA in patients with 
OSA.1;81-83 T2D is also associated with increased risk of RTA, but whether having both conditions 
increases the risk of RTA more than either one alone is unkown. 
OSA is associated with erectile dysfunction (ED) 
OSA and ED share many risk factors and their severity often goes in parallel.84. In one RCT (n=27), 1 
month of CPAP improved ED, but the findings are difficult to interpret, as the control group in this 
study was no treatment rather than sham CPAP; also, the study was unblended and its outcome was 
self-reported.85 Other uncontrolled/observational studies suggested beneficial effects of CPAP on ED 
and RCTs showed that sildenafil was superior to CPAP for managing ED.84;86-88. 
The impact of CPAP on glucose metabolism, CVD and QOL 
CPAP improved insulin sensitivity in patients with and without T2D in non-randomised trials,89;90 and 
in meta-analyses,91-93, especially for patients using CPAP >4 hours/night.94 Uncontrolled studies in 
patients with T2D95-99 showed that CPAP improves, postprandial hyperglycemia 96, glycaemic 
variability 97, and/or HbA1c 96;100. However, the only available randomized, controlled trial showed 
no impact of 3 months of CPAP on HbA1c.101 This may have been due to true lack of effect, the 
sample size, the relatively short duration of treatment and issues with CPAP compliance (3.6 
hours/night). Meta-analyses also showed that CPAP did not significantly improve HbA1c in patients 
with T2D.92;102 As the association between OSA and HbA1c seems stronger during REM,103 CPAP 
might have more impact on HbA1c at this sleep stage; CPAP use >4 hours/night may be required to 
improve HbA1c as REM occurs predominantly towards the end of the night. CPAP therefore cannot 
be recommended to improve glycaemic control in T2D and well-designed, RCTs are needed.104  
CPAP lowered BP in hypertensive patients with OSA in several RCTs and meta-analyses,105-107 and 
resulted in nocturnal dipping in BP in patients with resistant hypertension 107. However, valsartan 
was superior to CPAP (difference in mean 24 h BP: −7.0 mmHg [95%CI −10.9 to −3.1], p<0.001) in an 
8-week randomized, crossover study.108. CPAP was associated with a mean BP change of –6.81/–3.69 
mmHg 9–12 months in a retrospective cohort database study of patients with newly diagnosed OSA 
and pre-existing hypertension or T2D.109 CPAP lowered systolic and diastolic BP (149/80 mmHg to 
140/73 mmHg [p= 0.005/0.007 in another randomised trial.99 As yet, the impact of CPAP on incident 
hypertension is unclear.110 
CPAP reduced total and LDL cholesterol and increased HDL cholesterol but had no effect on 
triglycerides in a meta-analysis of 29 trials.111. Another meta-analysis included only RCTs (n=6) 
showed that CPAP reduced total cholesterol (particularly in younger, more obese patients, and those 
who used CPAP for a longer period) without effects on other lipid paramters.112 Three months of 
CPAP had no effect on the lipids in a RCT in T2D patients, but lipids were well controlled at 
baseline.99 Overall, the impact of CPAP on lipids might be less relevant than that of lipid lowering 
treatments. 
CPAP was associated with lower CVD incidence vs. no CPAP in some observational studies.64;65 
Randomisation of 723 patients with AHI ≥20 and ESS ≤10 to CPAP vs. no CPAP for 4 years had no 
impact on the incidence of a composite of hypertension and CVD (OR 0.83, 95 % CI 0.63–1.1; 
p=0.20).110 However, the combined outcome (but not CVD alone, perhaps due to a lack of events) 
was reduced in those who used CPAP ≥4 hours/night (OR 0.72, 95 % CI 0.52–0.98; p=0.04). The 
impact of CPAP on CVD in patients with T2D remains unknown. On one hand, the favourable impact 
of CPAP on CVD risk factors suggest that CPAP might lower CVD; but as the impact of CPAP on CVD 
risk factors may not be greater than currently available treatments then CPAP might not have an 
additional benefit. RCTs are again needed to answer this question. 
The impact of CPAP on microvascular complications in patient with T2D is limited to a small number 
of observational studies. In a cohort study form the UK, patients who were more compliant with 
CPAP had lower progression of DR.76 CPAP may support improved functionality rather than actual 
change in macular oedema.113 A RCT assessing the impact of CPAP on maculopathy is currently 
ongoing. CPAP was also associated with less eGFR decline in an observational study from the UK. 78 
Uncontrolled studies suggest that 2–6 months of CPAP might improve vitality, social functioning, 
mental health, physical health, and levels of independence, with the magnitude of improvement 
related to the baseline QoL impairment rather than OSA severity.80;114. However, another study 
found that the improvement in QoL on CPAP was similar irrespective of compliance.115. Data in T2D 
are lacking. 
Summary and conclusions 
OSA is very common in patients with T2D and is associated with impaired QoL, ED, CV risk factors, 
CVD and microvascular complications in patients with and without T2D. However, convincing 
evidence from RCTs in patients with T2D that CPAP treatment has favourable impacts on CVD, 
microvascular complications or QOL are still lacking. Evidence from general populations suggests 
that CPAP improves hypertension, hyperlipidaemia, insulin resistance, QOL and CVD. In addition, 
OSA symptoms are common in patients with T2D and CPAP will improve these symptoms.  
Most Diabetologists do not check for OSA in patients with T2D, despite its high prevalence in this 
population and despite a recommendation to do so by the IDF since 2008. This is further 
complicated with lack of consensus regarding the best way to screen for OSA in patients withT2D 
and the lack of data regarding the impact of CPAP and cost-effectiveness; which raises further 
challenges to diabetologists. However, and regardless of the impact of CPAP on diabetes-related 
outcomes, it is important to remember that OSA lowers the risk of road traffic accidents. In addition. 
Diabetologists should also be vigilant to diagnose OSA in patients with T2D in which CPAP might 
have a favourable impact such as patients who have OSA-related symptoms or patients with 
resistant hypertension or significant insulin resistance. Ongoing RCTs will clarify the impact of CPAP 
on diabetes-related outcomes, particularly glycaemic control and micro and macro vascular disease. 
In addition, several studies are examining the role of several biomarkers to aid screening for OSA in 
patients with T2D.   
 
Key points: 
- OSA is common in both the general population and in those with type 2 diabetes, with an 
association with obesity. 
- The IDF recommends screening patients with type 2 diabetes for OSA but practice varies and 
there is no consensus approach. 
- CPAP treatment has an impact on BP, cholesterol, insulin resistance, quality of life and 
possibly cardiovascular disease but the evidence in patients with T2D is limited. 
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